|
Synonyms
|
IL-1RP3, IL-1HY1, IL-1 delta, IL-1F5, IL-1ra homolog 1, IL-1L1
|
|
Species
|
Human
|
|
Accession
|
Q9UBH0
|
|
GeneID
|
26525
|
|
Source
|
Escherichia coli.
|
|
Molecular Weight
|
重组人白细胞介素-36受体拮抗剂蛋白蛋白Approximately 16.8 kDa, a single non-glycosylated polypeptide chain containing 154 amino acids.
|
|
Quantity
|
5µg/25µg/1000µg
|
|
AA Sequence
|
VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD
|
|
Purity
|
重组人白细胞介素-36受体拮抗剂蛋白蛋白> 95 % by SDS-PAGE and HPLC analyses.
|
|
Biological Activity
|
Fully biologically active when compared to standard. The ED50 as determined by inhibiting IL-36 beta induced IL-8 secretion by human preadipocytes is less than 1.0 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 20 ng/ml of recombinant human IL-36 beta.
|
|
Physical Appearance
|
Sterile Filtered White lyophilized (freeze-dried) powder.
|
|
Formulation
|
重组人白细胞介素-36受体拮抗剂蛋白蛋白Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
|
|
Endotoxin
|
Less than 1 EU/µg of rHuIL-36RA as determined by LAL method.
|
|
Reconstitution
|
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
|
|
Storage
|
This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|
重组人白细胞介素-36受体拮抗剂蛋白蛋白
|
|
|
SDS-PAGE
|
|
|
Reference
|
1. Born TL, Smith DE, Garka KE, et al. 2000. J Biol Chem. 275:41528.
2. Dunn EF, Gay NJ, Bristow AF, et al. 2003. Biochemistry. 42:10938-44.
3. Barton JL, Herbst R, Bosisio D, et al. 2000. Eur J Immunol. 30:3299-308.
4. Debets R, Timans JC, Homey B, et al. 2001. J Immunol. 167:1440-6.
5. Towne JE, Renshaw BR, Douangpanya J, et al. 2011. J Biol Chem. 286:42594-602.
|
|
Background
|
Interleukin-36 receptor antagonist (IL-36RA) is a secreted protein which belongs to the interleukin 1 cytokine family (IL-1 family) and it is predominantly expressed in keratinocytes but not in fibroblasts, endothelial cells or melanocytes. IL-36RA has been reported to antagonize the biological activity of IL-36α (IL-1F6), IL-36β (IL-1F8), and IL-36γ (IL-1F9). Furthermore, it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). In addition, The receptor for IL-36RA has not been positively identified. Indirect evidence suggests it is IL-1Rrp2. Recombinant human IL-36 RA contains 154 amino acid residues and it shares 91 % a.a. sequence identity with murine IL-36RA.
|
